Volume 56, Issue 2, December 2018, Pages 115-120 Choi EY, Park CY, Ho SH, Park SJ, Kim D, Han B, Kim SH
While the latest Phase 2b trial in the GLP-1RA drug met its primary endpoint of showing statistically significant change in body weight from baseline, the pharma said that it will still discontinue the program
Current Limitations of the Evidence Cagrilintide is an investigational compound
Clinical trials, particularly those involving alpha-lipoic acid, provide evidence supporting the benefits of antioxidant therapy in enhancing nerve function
Women are frequently diagnosed and uniquely at risk because pregnancy heavily stresses the bodys energy demands and further depletes carnitine levels, leading to a metabolic crisis [1] [8]